Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations

Most Her2 testing guidelines recommend that all cases scoring Her2 2+ by immunohistochemistry should be analyzed by fluorescent in situ hybridization (FISH) to determine HER2 status to confirm eligibility for Trastuzumab therapy in breast cancer. The aim of our study was to determine HER2 gene and chromosome 17 (CEN17) status in a series of 108 Her2 2+ consecutive cases and study the correlation between pathological characteristics of the tumors and HER2 amplification. Invasive breast cancers were tested by FISH using the Dako HER2 FISH pharmDx® kit. The Her2 immunohistochemistry protocol was performed using the polyclonal AO485 antibody (Dako®) diluted to 1:1500. HER2 and CEN17 status were correlated to tumor SBR grade, mitotic count, estrogen receptor, progesterone receptor status and percentage of Her2 immunohistochemistry-positive cells. Following Food and Drug Administration guidelines, ie, HER2/CEN17 ratio ≥2 and an HER2 copy number >4, amplified cases were observed in 36 (33%) and 49 (45%) cases, respectively, and following American Society of Clinical Oncology/College of American Pathologists guidelines, ie, HER2/CEN17 ratio >2.2 and an HER2 copy number >6, amplified cases represented 30 and 24% of the study population, respectively. Chromosome 17 polysomy (CEN17 >2.25) was observed in 39 (36%) tumors. Significant positive correlations were found between FISH HER2 amplified cases and Her2 immunostaining >60% (P=1.1.10−5), SBR grade 3 (P=0.0001), nuclear atypia (P=0.03) and mitotic count (P=0.008). By multivariate analysis, Her2 immunostaining >60% (P<10−3) and SBR grade 3 (P<10−3) were independent factors predicting HER2 amplification status irrespective to cutoff guidelines. All SBR grade 3 cases with more than 60% Her2+ cells had an HER2/CEN17 ratio ≥2, only one had a ratio ≤2.2. In our series of consecutive Her2 2+ cases, one-third demonstrated HER2 amplification, and one-third had chromosome 17 polysomy. Pathological factors, in particular SBR grade 3 and more than 60% Her2+ cells, were significantly correlated with HER2 amplification.

[1]  C. Sotiriou,et al.  Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer , 2006, Molecular Cancer Therapeutics.

[2]  J. Winston,et al.  HER-2/neu evaluation in breast cancer are we there yet? , 2004, American journal of clinical pathology.

[3]  T. Henkel,et al.  Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy , 2007, Journal of Clinical Pathology.

[4]  T. Grogan,et al.  The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.

[5]  M. Mottolese,et al.  Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. , 2006, European journal of cancer.

[6]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[7]  T. Grogan,et al.  Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Sotiriou,et al.  Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice , 2005, Clinical Cancer Research.

[9]  A. Luini,et al.  HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. , 2007, European journal of cancer.

[10]  S. Serrano,et al.  Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry , 2005, Breast Cancer Research.

[11]  Lajos Pusztai,et al.  Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.

[12]  B. Mcclintock,et al.  The Stability of Broken Ends of Chromosomes in Zea Mays. , 1941, Genetics.

[13]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[14]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[15]  M. Ladanyi,et al.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. , 2003, The Journal of molecular diagnostics : JMD.

[16]  F. Toledo,et al.  Gene amplification mechanisms: the role of fragile sites. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[17]  R. Gelber,et al.  Life with consequences of breast cancer: pregnancy during and after endocrine therapies. , 2004, Breast.

[18]  Matteo Brunelli,et al.  HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. , 2008, American journal of clinical pathology.

[19]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[20]  F. Penault-Llorca,et al.  Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification , 2007, Clinical Cancer Research.

[21]  A. Vincent-Salomon,et al.  Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * Study , 2003, Histopathology.

[22]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[23]  M. Ladanyi,et al.  HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. , 2004, American journal of clinical pathology.

[24]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.